<unk>  is used in conjunction with castration, either via bilateral orchiectomy or gonadotropin-releasing hormone analogue (GnRH analogue) therapy, as a method of androgen deprivation therapy in the treatment of NM-CRPC. It is also a promising potential treatment for metastatic castration-resistant prostate cancer (mCRPC), which the NSAA enzalutamide and the androgen synthesis inhibitor abiraterone acetate are used to treat. Available forms<unk>  is provided in the form of 60 mg oral tablets. It is taken at a dosage of 240 mg once per day (four tablets) when used in the treatment of NM-CRPC.
Apalutamide
Darolutamide
Bicalutamide
Nilutamide
Acetothiolutamide
Topilutamide
Flutamide
Enzalutamide